^
    11d
    Combined CRS With HIPEC in Women With Inadvertently Morcellated uLMS (clinicaltrials.gov)
    P=N/A, N=19, Completed, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New trial • Surgery
    |
    docetaxel
    20d
    mTOR inhibitor in the treatment of TFE-positive advanced maligmnant PEComa of the uterus: a case report and literature review. (PubMed, Ginekol Pol)
    The patient described herein had a TFE-positive uterine malignant PEComa with lung metastasis and responded well to the mTOR inhibitor, everolimus. Close follow-up in the last 3 years showed remission without recurrence or progression.
    Review • Journal • Metastases
    |
    TSC1 (TSC complex subunit 1)
    |
    everolimus
    1m
    A rare case aggressive of uterine leiomyosarcoma: a case report. (PubMed, Pan Afr Med J)
    As the cases are rare in nature, screening is impractical. Hence, the diagnosis of uterine leiomyosarcoma is done by histopathologic examination after surgery.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    1m
    Integrated bioinformatics reveals genetic links between visceral obesity and uterine tumors. (PubMed, Mol Genet Genomics)
    These findings deepen our understanding of disease etiology and offer promising avenues for drug repurposing. Experimental validation is needed to translate these insights into clinical applications and innovative treatments.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • TYMS (Thymidylate Synthetase) • APOE (Apolipoprotein E)
    2ms
    Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    temozolomide • Cabometyx (cabozantinib tablet)
    2ms
    NNMT overexpression is an adverse prognostic factor in uterine leiomyosarcoma. (PubMed, Turk J Med Sci)
    The consequences of NNMT overexpression, such as the activation and inactivation of oncoproteins and tumor suppressor proteins, respectively, as well as the enrichment of the cancer stem cell population, overlap with the major mechanisms responsible for poor prognosis in mesenchymal tumors. NNMT may be investigated further in the context of antitumor treatment in patients with mesenchymal malignancies.
    Journal
    |
    NNMT (Nicotinamide N-Methyltransferase)
    2ms
    Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. (PubMed, Cells)
    Furthermore, inhibiting BET proteins with their small, potent inhibitors (JQ1 and I-BET 762) significantly inhibited the uLMS proliferation dose-dependently via cell cycle arrest. The connections between BET proteins and crucial biological pathways provide a fundamental structure to better understand uterine diseases, particularly uLMS pathogenesis. Accordingly, targeting the vulnerable epigenome may provide an additional regulatory mechanism for uterine cancer treatment.
    Journal
    |
    BRD4 (Bromodomain Containing 4) • BRD2 (Bromodomain Containing 2) • BRD3 (Bromodomain Containing 3)
    |
    JQ-1 • molibresib (GSK525762)
    4ms
    POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY. (PubMed, Georgian Med News)
    LMP2/β1i, cyclin E1, and Ki-67/MIB1 may be candidate factors for biomarkers of human uterine leiomyosarcoma. Further large-cohort clinical trials should be conducted to establish treatments and diagnostics for uterine mesenchymal tumors.
    Journal
    |
    CCNE1 (Cyclin E1)
    4ms
    Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma. (PubMed, Anticancer Res)
    The Hippo pathway is implicated in uLMS oncogenesis, since nuclear expression of YAP1 was detected in 17 (53.1%) of the 32 patients with immunohistochemistry and YAP1 amplification was found in 8 (25%) patients.
    Journal
    |
    YAP1 (Yes associated protein 1)
    4ms
    L-UteCIN: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour (clinicaltrials.gov)
    P2, N=198, Not yet recruiting, UNICANCER
    New P2 trial
    |
    doxorubicin hydrochloride • Yondelis (trabectedin)
    4ms
    Myxoid leiomyosarcoma of the oviduct and uterus in a Cockatiel (Nymphicus hollandicus). (PubMed, Vet Med Sci)
    Myxoid LMS is an extremely rare neoplasm in animals. To our knowledge, myxoid LMS has not been reported previously in pet birds.
    Journal
    |
    VIM (Vimentin)
    5ms
    Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Cabometyx (cabozantinib tablet)
    5ms
    Impact of comprehensive genomic profiling on the diagnosis and clinical management of mesenchymal tumours (ECP 2024)
    In our practice, a significant proportion of patients were prescreened with a smaller NGS panel. Despite this fact, we still found actionable alterations in 23,8% of the patients, which is in line with those reported in the literature (22-61%). Our results demonstrate that CGP can provide useful additional information and can be beneficial in the clinical management of patients with mesenchymal tumours.
    Clinical • Tumor mutational burden • PARP Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • HRD (Homologous Recombination Deficiency) • MDM2 (E3 ubiquitin protein ligase) • MYOD1 (Myogenic Differentiation 1)
    |
    TMB-H • HRD • CDK4 amplification • MDM2 amplification + CDK4 amplification • CDK4 mutation • High HRD score
    |
    Oncomine™ Comprehensive Assay Plus
    5ms
    PLAG1-Rearranged Uterine Sarcomas: A Study of 11 Cases Showing a Wide Phenotypical Spectrum Not Limited to Myxoid Leiomyosarcoma-like Morphology. (PubMed, Mod Pathol)
    Our study documents a much broader morphological spectrum of PLAG1-US than previously reported, encompassing but not limited to M-LMS-like morphology with occasional heterologous (particularly adipocytic) differentiation. Since it is currently difficult to precisely define their line of differentiation, for the time being, we suggest using a descriptive name PLAG1-rearranged uterine sarcoma.
    Journal
    |
    PLAG1 (PLAG1 Zinc Finger) • FRMD6 (FERM Domain Containing 6) • PTK2 (Protein Tyrosine Kinase 2) • PUM1 (Pumilio RNA Binding Family Member 1) • TRPS1 (Transcriptional Repressor GATA Binding 1)
    5ms
    2‑D08 mediates notable anticancer effects through multiple cellular pathways in uterine leiomyosarcoma cells. (PubMed, Oncol Rep)
    It was concluded that 2‑D08 exerts antitumor effects in Ut‑LMS cells by modulating multiple signaling pathways and that 2‑D08 may be a promising candidate for the treatment of human Ut‑LMS. The present study expanded and developed knowledge regarding Ut‑LMS management and indicated that 2‑D08 represents a notable finding in the exploration of fresh treatment options for such cancerous tumors.
    Journal
    |
    CASP3 (Caspase 3) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • TAGLN (Transgelin)
    5ms
    Inhibition of aberrantly overexpressed Polo-like kinase 4 is a potential effective treatment for DNA damage repair-deficient uterine leiomyosarcoma. (PubMed, Clin Cancer Res)
    Uterine LMS with DNA repair defects is sensitive to PLK4 inhibition because of the effects of chromosome missegregation and increased DNA damage. Loss-of-function BRCA2 alterations or pharmacological inhibition of ATM enhanced the efficacy of PLK4 inhibitor. Genomic profiling of an advanced-stage or recurrent uterine LMS may guide therapy.
    Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • PLK4 (Polo Like Kinase 4)
    |
    ocifisertib (CFI-400945) • AZD0156
    5ms
    Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma. (PubMed, Int J Gynecol Pathol)
    Stathmin was the only prognosticator in a multivariate analysis limited to patients with FIGO stage I disease (P = 0.013). In conclusion, Stathmin expression is strongly associated with poor survival in uLMS and may be a new prognostic marker in this malignancy.
    Journal
    |
    ATRX (ATRX Chromatin Remodeler) • HMGA2 (High mobility group AT-hook 2) • DAXX (Death-domain associated protein)
    6ms
    FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (clinicaltrials.gov)
    P2, N=17, Completed, Frederic Amant | Recruiting --> Completed | N=200 --> 17
    Trial completion • Enrollment change • Metastases
    |
    ER (Estrogen receptor)
    |
    fulvestrant
    6ms
    Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (clinicaltrials.gov)
    P2/3, N=190, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Lynparza (olaparib) • temozolomide • pazopanib • Yondelis (trabectedin)
    6ms
    Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. (PubMed, Oncologist)
    uLMS displays a significant frequency of somatic BRCA2alt homDel. Considering their dismal prognosis, further investigation is warranted to test the use of PARPi in uLMS, and particularly in the setting of BRCA1/2 alterations.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD50 (RAD50 Double Strand Break Repair Protein) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • FANCL (FA Complementation Group L) • FANCI (FA Complementation Group I) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • FANCB (FA Complementation Group B) • FANCC (FA Complementation Group C)
    |
    BRCA2 mutation
    |
    Zejula (niraparib)
    6ms
    Pazopanib vs. Pazopanib Plus Gemcitabine (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, North Eastern German Society of Gynaecological Oncology | Recruiting --> Active, not recruiting | N=107 --> 58 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    gemcitabine • pazopanib
    7ms
    PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade. (PubMed, Clin Transl Med)
    Our findings indicate that aberrant PI3K/mTOR pathway activation contributes to immune escape in uLMS and provides a rationale for combining PI3K/mTOR inhibition with ICB for the treatment of this patient population.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    7ms
    Characterizing TP53 mutations in bone and soft tissue sarcoma. (ASCO 2024)
    We queried the missense variants for the 800 most frequent variants recorded in the International Agency for Research on Cancer R20 (IARC), which were structurally characterized based on their impact on TP53 protein and rescue potencies with arsenic trioxide (ATO) in vitro (Song et al... This analysis highlights the heterogenous landscape of TP53 mutations in bone and soft tissue sarcomas. Structural variants are prevalent in sarcoma and occur at hotspots that may represent novel drug targets in the future.
    TP53 (Tumor protein P53)
    |
    MSK-IMPACT
    |
    arsenic trioxide
    7ms
    FOXO3a deregulation in uterine smooth muscle tumors. (PubMed, Clinics (Sao Paulo))
    In summary, the outcomes of the present study suggest that the imbalance in FOXO3a within Uterine Smooth Muscle Tumors might arise from both protein phosphorylation and miRNA activity. FOXO3a could emerge as a promising therapeutic target for individuals with Unusual Leiomyomas and Leiomyosarcomas (ULM and LMS), offering novel directions for treatment strategies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MIR155 (MicroRNA 155) • FOXO3 (Forkhead box O3) • MIR96 (MicroRNA 96) • Let-7c (MicroRNA Let-7c)
    |
    HER-2 expression • VEGFA expression
    7ms
    New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins. (PubMed, Exp Ther Med)
    In conclusion, SFRP4 may suppress the viability and migration, and enhance the adhesion of sarcoma cells. These results suggested that SFRP4 could be considered as a novel therapeutic target for uterine sarcoma.
    Journal
    |
    SFRP4 (Secreted frizzled-related protein 4)
    |
    KIT expression
    7ms
    Uterine myxoid leiomyosarcoma: identification of a novel PLAG1 fusion partner. (PubMed, Pathology)
    No abstract available
    Journal
    |
    PLAG1 (PLAG1 Zinc Finger)
    8ms
    Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    8ms
    Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma. (PubMed, Anticancer Res)
    Expression levels of MMP2 and MMP9 were upregulated in malignant uLMS tumors when compared with those in benign uterine leiomyoma tumors. Increased MMP2 expression might promote uLMS invasion and migration. MMP9 overexpression might be related to uLMS occurrence; however, it protects against uLMS invasion and metastasis. MMP2 and MMP9 may be potential predictors of uLMS cell proliferation, metastasis, and prognosis. These findings could be helpful in developing new strategies for diagnosing and treating uLMS.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
    |
    MMP9 overexpression
    8ms
    Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas. (PubMed, Mod Pathol)
    All cases showed high NR4A3 RNA expression levels and NOR1 (NR4A3) nuclear staining similar to salivary gland acinic cell carcinoma and a subset of extraskeletal myxoid chondrosarcomas harboring NR4A3 rearrangement. NOR1 (NR4A3) immunohistochemistry may serve as a useful diagnostic marker of NR4A3 fusion-positive gynecologic leiomyosarcomas.
    Journal
    |
    NR4A3 (Nuclear receptor subfamily 4 group A member 3) • MME (Membrane Metalloendopeptidase) • SLCO5A1 (Solute Carrier Organic Anion Transporter Family Member 5A1)
    8ms
    Uterine Leiomyosarcoma Associated With Perivascular Epithelioid Cell Tumor: A Phenomenon of Differentiation/Dedifferentiation and Evidence Suggesting Cell-of-Origin. (PubMed, Am J Surg Pathol)
    We hypothesize that LMSs containing smooth muscle progenitor cells may give rise to divergent, lineage-specific PEComatous lesions through differentiation or dedifferentiation. While we do not dispute the recognition of PEComas as a distinct entity, we advocate the hypothesis that modified smooth muscle cells represent the origin of a subset of PEComas, and our case series provides evidence to suggest this theory.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • FH (Fumarate Hydratase) • GPNMB (Glycoprotein Nmb) • CTSK (Cathepsin K)
    |
    TP53 mutation • RB1 expression • TP53 expression • TP53 R196*
    8ms
    Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma. (PubMed, Clin Cancer Res)
    Compared to traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • RB1 mutation • ATRX mutation
    9ms
    SAVE: Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (clinicaltrials.gov)
    P3, N=188, Recruiting, University of Utah | Active, not recruiting --> Recruiting | N=108 --> 188 | Trial completion date: Sep 2024 --> Oct 2029 | Trial primary completion date: Dec 2021 --> Nov 2026
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    9ms
    Uterine leiomyosarcoma cell-derived extracellular vesicles induce the formation of cancer-associated fibroblasts. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    miR-654-3p and miR-369-3p are highly expressed in ULMS-derived EVs, indicating that these EV-related miRNAs induce the formation of cancer-associated fibroblasts.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle)
    9ms
    Letrozole in Uterine Leiomyosarcoma (clinicaltrials.gov)
    P2, N=40, Recruiting, GOG Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor)
    |
    letrozole
    9ms
    Molecular profile and actionability of sarcomas with next-generation sequencing: Insights from a single institution in Brazil (Sarcoma-RC 2024)
    Despite the limitation of sample size, our study identified actionable alterations in 28% of tumor samples submitted to CGP. A high level of evidence of clinical activity according to OncoKB criteria was noted in 41% of actionable alterations. These findings underscore the importance of comprehensive genomic profiling in managing sarcomas.
    Clinical • Tumor mutational burden • Next-generation sequencing
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • CCNE1 (Cyclin E1) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • KDM6A (Lysine Demethylase 6A) • MDM4 (The mouse double minute 4) • MUTYH (MutY homolog) • PAX3 (Paired Box 3)
    |
    TMB-H
    |
    TruSight Oncology 500 Assay
    9ms
    CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma (USCAP 2024)
    Overall, in our uLMS analysis, CDK4 and/or MDM2 amplification was identified in a small subset (2%) of uLMS, the majority of which are TP53/RB1-wildtype. This may suggest that CDK4/MDM2 amplification can be an alternative tumorigenic mechanism in this distinct class of uLMS, which may have therapeutic clinical implications, including possible use of specific cyclin-dependent kinase inhibitors.
    Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • RB1 wild-type • CDK4 mutation
    |
    FoundationOne® Heme CDx
    9ms
    Fumarate-Deficient Uterine Leiomyosarcoma: Molecular Confirmation of Four Cases (USCAP 2024)
    While exceedingly rarely, FH mutations may be found in uLMS. Confirmation of FH deficiency should not preclude the diagnosis of sarcoma in smooth muscle neoplasms that meet histologic criteria for malignancy.
    Clinical
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • FH (Fumarate Hydratase)
    |
    TP53 mutation • MET mutation • RB1 deletion • ATRX mutation • RB deletion
    |
    FoundationOne® Heme CDx
    9ms
    CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma (USCAP 2024)
    Overall, in our uLMS analysis, CDK4 and/or MDM2 amplification was identified in a small subset (2%) of uLMS, the majority of which are TP53/RB1-wildtype. This may suggest that CDK4/MDM2 amplification can be an alternative tumorigenic mechanism in this distinct class of uLMS, which may have therapeutic clinical implications, including possible use of specific cyclin-dependent kinase inhibitors.
    Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • RB1 wild-type • CDK4 mutation
    |
    FoundationOne® Heme CDx
    11ms
    Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Cabometyx (cabozantinib tablet)
    11ms
    Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma. (PubMed, Cells)
    Ad-Sur-NIS as a PET scan reporter is a promising imaging biomarker that can differentiate uterine LMS from LM using F18-NaBF as a radiotracer. As a new diagnostic method, the F18 NaBF PET/CT scan can provide a much-needed tool in clinical practices to effectively triage women with suspicious uterine masses and avoid unnecessary invasive interventions.
    Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    11ms
    Sarcomas with RAD51B Fusions are Associated with a Heterogeneous Phenotype. (PubMed, Mod Pathol)
    Our results expand the spectrum of sarcomas with RAD51B-fusions, demonstrating variable clinical presentations, morphologic spectrum, and fusion partners. These tumors have a predilection for a uterine location, with either LMS, PEComa or undifferentiated phenotypes, and are associated with an aggressive clinical course.
    Journal
    |
    RAD51B (RAD51 Paralog B) • TSC1 (TSC complex subunit 1) • HMGA2 (High mobility group AT-hook 2)
    |
    FusionPlex® Dx
    11ms
    Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working (clinicaltrials.gov)
    P2/3, N=190, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | N=70 --> 190
    Enrollment open • Enrollment change • Metastases
    |
    Lynparza (olaparib) • temozolomide • pazopanib • Yondelis (trabectedin)